Payment overview · 2025
General Payments
$208.17
12 reported records · 7 companies
Healthcare provider profile · identity verified
William L Cooper
Allopathic & Osteopathic Physicians|Internal Medicine · THOMASVILLE, GA · NPI 1477512663
Verified facts
What the public records show
CMS Open Payments records show William L Cooper received $208.17 in general payments during 2025 across 12 reported records.
PFIZER INC. accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.77 | 31.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.49 | 21.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.40 | 15.1% | 2 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $26.66 | 12.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.36 | 8.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.65 | 6.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.84 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $208.17 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.40 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.37 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.37 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $29.44 | 1 | 2025 |
Source payment records
|
|||||
| ADBRY Normalized: adbry |
Biological | LEO Pharma Inc. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 217 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
70 | 70 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
55 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
217 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1086 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 618 | 135 |
| Potassium Chloride | Potassium Chloride | 511 | 108 |
| Omeprazole | Omeprazole | 378 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 80 |
| Metformin Hcl | Metformin Hcl | 366 | 73 |
| Furosemide | Furosemide | 363 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 349 | 80 |
| Losartan Potassium | Losartan Potassium | 343 | 82 |
| Gabapentin | Gabapentin | 324 | 80 |
| Lisinopril | Lisinopril | 321 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 65 |
| Alendronate Sodium | Alendronate Sodium | 261 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 65 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 236 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 229 | 42 |
| Eliquis | Apixaban | 217 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 49 |
| Chlorthalidone | Chlorthalidone | 215 | 45 |
| Simvastatin | Simvastatin | 184 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 49 |
| Farxiga | Dapagliflozin Propanediol | 174 | 33 |
| Tramadol Hcl | Tramadol Hcl | 171 | 67 |
| Carvedilol | Carvedilol | 170 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 37 |
| Trazodone Hcl | Trazodone Hcl | 161 | 37 |
| Sertraline Hcl | Sertraline Hcl | 160 | 41 |
| Allopurinol | Allopurinol | 156 | 42 |
| Jardiance | Empagliflozin | 142 | 25 |
| Meloxicam | Meloxicam | 137 | 42 |
| Spironolactone | Spironolactone | 137 | 32 |
| Alprazolam | Alprazolam | 127 | 24 |
| Prednisone | Prednisone | 123 | 70 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 27 |
| Methylprednisolone | Methylprednisolone | 115 | 95 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 107 | 95 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 14 |
| Famotidine | Famotidine | 106 | 26 |
| Lorazepam | Lorazepam | 105 | 33 |
| Nifedipine Er | Nifedipine | 103 | 24 |
| Ozempic | Semaglutide | 99 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 22 |
| Synthroid | Levothyroxine Sodium | 95 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 88 | 20 |
| Metformin Hcl Er | Metformin Hcl | 85 | 23 |
| Ezetimibe | Ezetimibe | 84 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 79 | 16 |
| Bupropion Xl | Bupropion Hcl | 77 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 70 | 70 |
| Montelukast Sodium | Montelukast Sodium | 67 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 60 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 25 |
| Celecoxib | Celecoxib | 59 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 13 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 45 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 13 |
| Glimepiride | Glimepiride | 50 | 16 |
| Donepezil Hcl | Donepezil Hcl | 49 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 35 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Atenolol | Atenolol | 41 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Ramipril | Ramipril | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 31 |
| Meclizine Hcl | Meclizine Hcl | 38 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Clonidine | Clonidine | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Calcitriol | Calcitriol | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 30 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 19 |
| Colchicine | Colchicine | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 20 |
| Ondansetron Odt | Ondansetron | 28 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 23 | 23 |
| Bumetanide | Bumetanide | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Etodolac | Etodolac | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $208.17 · 12 records | PFIZER INC. | ABRYSVO, ADBRY, COMIRNATY, ELIQUIS, EVENITY, KISUNLA, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error